Mumbai, Aug. 8 -- The approval is for an additional indication of the drug in the treatment of HER2-positive breast cancer.

The approval covers Trastuzumab Deruxtecan Powder for Concentrate for Solution for Infusion 100 mg (ENHERTU) for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant Trastuzumab, with or without Pertuzumab, and taxane-based treatment.

The regulatory approval paves the way for the marketing of Enhertu in India for the specified additional indication, subject to receipt of related statutory approvals, if any.

AstraZeneca Pharma India reported a 22.95% year-on-year decline in standalone net profit to Rs 44.88 crore for the ...